Navigation Links
What is the effect of fluoxetine on mast cell?
Date:12/23/2008

Mast cells are now recognized as "granular cells of the connective tissue", whose activation exacerbates allergic immune responses and as key players in the establishment of innate immunity as well as modulators of adaptive immune responses. The role of mast cells in the gastrointestinal mucosa is not only to react to antigens, but also to actively regulate the barrier and transport properties of the intestinal epithelium. In clinical studies, it has become clear that psychological factors, especially anxiety and depression, play an important role in gastrointestinal diseases by precipitating exacerbation of symptoms. Fluoxetine hydrochloride (fluoxetine) is a kind of selective serotonin reuptake inhibitors (SSRIs), which belong to a class of antidepressants used in the treatment of depression and anxiety disorders.

The research team led by He-Shen Luo, from the Renmin Hospital of Wuhan University of China, investigated the effects of fluoxetine on mast cell morphology and rMCP-1 expression in gastric antrum in a rat model of depression. This will be published on December 7, 2008 in the World Journal of Gastroenterology.

A Sprague-Dawley rat model of chronic stress-induced depression was established. Fifty experimental rats were randomly divided into the five groups: normal control group, fluoxetine + normal control group, depressed model group, saline + depressed model group, and fluoxetine + depressed model group. Laser scanning confocal microscopy (LSCM) immunofluorecence and RT-PCR techniques were used to investigate rMCP-1 expression in gastric antrum. Mast cell morphology was observed under transmission electron microscopy.

They found that depression induced mast cell proliferation, activation, and granule hyperplasia. Compared with the normal control group, the average immunofluorescence intensity of gastric antrum rMCP-1 significantly increased in depressed model group (37.4 7.7 vs 24.5 5.6, P < 0.01) or saline + depressed model group (39.9 5.0 vs 24.5 5.6, P < 0.01), while there was no significant difference between fluoxetine + normal control group (23.1 3.4) or fluoxetine + depressed model group (26.1 3.6) and normal control group. The average level of rMCP-1mRNA of gastric antrum significantly increased in depressed model group (0.759 0.357 vs 0.476 0.029, P < 0.01) or saline + depressed model group (0.781 0.451 vs 0.476 0.029, P < 0.01 ), while no significant difference was found between fluoxetine + normal control group(0.460 0.027) or fluoxetine + depressed model group (0.488 0.030) and normal control group. Fluoxetine showed partial inhibitive effects on mast cell ultrastructural alterations and de-regulated rMCP-1 expression in gastric antrum of the depressed rat model.

These findings will conduce to understand that chronic heterotypic stress may induce the immune responses in gastric mucosa. Treatment with fluoxetine can ameliorate pathological changes in gastric antrum of depressed rat model, suggesting that SSRIs are an effective therapeutic agent for some gastroduodenal diseases caused by psychological factors.


'/>"/>

Contact: Lai-Fu Li
wjg@wjgnet.com
0086-105-908-0039
World Journal of Gastroenterology
Source:Eurekalert

Related medicine news :

1. New study shows that a cough medicine ingredient could effectively treat prostate cancer
2. Common treatment for mens pelvic pain proves ineffective, Queens-led study shows
3. Experts Say Blood Sugar Guidelines Remain Effective
4. Cardiac stent patients with diabetes may benefit from drug that counteracts the effects of leptin
5. The Obama Effect: New Job Trends to Watch in 2009
6. MRI scans can predict effects of MS flare-ups on optic nerve
7. The profound effects of numbing agents
8. Precision Optics Corporation to Effect Reverse Split and Ticker Symbol Change
9. Treadmill Desks More Effective in Decreasing Prostate Cancer Risks Than Vitamin and Antioxidant Supplements
10. New Resource for No Side Effect Drugs
11. New therapy prevents dangerous side effect for lymphoma patients
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:6/28/2017)... Billings, MT (PRWEB) , ... June 28, 2017 ... ... that provides insurance management and financial planning assistance to clients in southern Montana, ... outreach programs offered by Zoo Montana. , The outreach programs offered by Zoo ...
(Date:6/28/2017)... Cincinnati, OH (PRWEB) , ... June 28, 2017 ... ... and financial consulting firm servicing communities throughout the greater Cincinnati metropolitan area, is ... help provide temporary lodgings for families with children receiving treatment in nearby hospitals. ...
(Date:6/27/2017)... ... June 27, 2017 , ... DrugDev understands that for many sites, ... the sponsor to pay them correctly and on time. As the search for high-performing ... that encourage sites to work on their studies. , At a complimentary live ...
(Date:6/27/2017)... ... 2017 , ... The Congressional Budget Office (CBO) projects that the Better Care ... Protection and Affordable Care Act (ACA), would result in 22 million Americans losing their ... , More than 20 million Americans have gained health insurance under the ACA, and ...
(Date:6/27/2017)... Beverly Hills, California (PRWEB) , ... June 27, 2017 , ... ... implants market has been projected to reach a staggering $6.81 billion by the year ... implants are rising at a faster rate than those made from titanium. Los Angeles ...
Breaking Medicine News(10 mins):
(Date:6/20/2017)... Netherlands and LAGUNA HILLS, Calif. ... the presentation of new data that validate the use ... risk stratify patients with multiple myeloma (MM). In a ... the European Hematology Association (EHA) in Madrid, ... value of MMprofiler for identifying high-risk elderly patients. ...
(Date:6/16/2017)... -- Exactly 50 years ago today, the Monterey Pop Festival opened ... the San Francisco "Summer of Love."  To celebrate the anniversary, ... in strategic market research portals that it will begin delivering ... Northern Light,s "Summer of Love (For Our Customers)."  ... ...
(Date:6/13/2017)... 2017 Zimmer Biomet Holdings, Inc. (NYSE and SIX: ... the U.S. Food and Drug Administration (FDA) has notified the ... to its Zhejiang, China manufacturing facility ... "The successful clearance of the Warning Letter related to our ... a measure of the progress we have made in our ...
Breaking Medicine Technology: